Matrixx Banks On Oral Cold Remedies And A Severe Flu Season
This article was originally published in The Tan Sheet
Executive Summary
Migrating customers to oral forms of its Zicam cold remedies is more critical for Matrixx Initiatives now that FDA refused to reverse its order to pull from the market the intranasal version of the zinc-containing cold products